Alendronate Can Be Continued Without Interruption for Root Canal Procedures
Root canal therapy does not require stopping or delaying alendronate, and the medication can be safely continued throughout the procedure and resumed immediately afterward. Unlike tooth extraction, root canal treatment is a non-invasive endodontic procedure that preserves the tooth and does not expose bone, thereby carrying minimal to no risk of osteonecrosis of the jaw (ONJ).
Key Clinical Reasoning
Root Canal vs. Extraction: Critical Distinction
Root canal therapy is fundamentally different from tooth extraction in terms of ONJ risk:
- Root canals preserve teeth and avoid bone exposure, which is the primary trigger for bisphosphonate-related ONJ 1
- Tooth extraction carries a 0.5% risk of developing ONJ in patients on bisphosphonates 1
- Root canal therapy may actually reduce ONJ risk by eliminating the need for extraction 2
No Drug Holiday Required
The evidence regarding bisphosphonate interruption specifically addresses invasive procedures:
- The American Dental Association does not recommend stopping bisphosphonates for dental procedures 1
- Drug holidays are only considered controversial for tooth extraction or implant placement, not root canals 1
- When invasive procedures ARE planned, the American Association of Oral and Maxillofacial Surgeons recommends a 2-month drug holiday only for patients on bisphosphonates >4 years 1
Practical Management Algorithm
For root canal procedures:
- Continue alendronate without interruption - no drug holiday needed
- Take alendronate according to normal dosing schedule (weekly or daily) 3
- Maintain routine dental hygiene 1
- Complete the root canal procedure without delay
Only if extraction becomes necessary:
- Consider the patient's bisphosphonate duration (>4 years increases ONJ risk to 0.21%) 1
- Evaluate if a 2-month drug holiday is appropriate based on fracture risk
- Defer initiation of new bisphosphonate therapy until extraction site heals 1
Important Caveats
Do not confuse root canal therapy with extraction. Root canal treatment is conservative, preserves the tooth structure, and should be the preferred approach for teeth with pulpal/periapical disease in bisphosphonate-treated patients specifically because it avoids the ONJ risk associated with extraction 2.
The absolute risk of ONJ in osteoporosis patients on oral bisphosphonates is extremely low (0.001% to 0.01% overall, rising to 0.21% after >4 years of therapy) 1. This risk is primarily associated with procedures that expose bone, not endodontic therapy.